New review shows why antidepressants often fail in Alzheimer’s and Parkinson’s depression

By Hugo Francisco de SouzaReviewed by Susha Cheriyedath, M.Sc.Jul 7 2026

As depression accelerates suffering in Alzheimer’s and Parkinson’s disease, researchers argue that the next generation of treatments must target the damaged brain circuits and molecular pathways that standard antidepressants often miss.

Review: Depression in neurodegenerative disease: neurobiological mechanisms and emerging treatments. Image Credit: Hanchana Art / Shutterstock

In a recent review published in the journal Molecular Psychiatry, researchers collated decades of literature on the co-occurrence of depression with neurodegenerative diseases, particularly Alzheimer's disease (AD) and Parkinson's disease (PD), to help explain why standard antidepressants often show little or no efficacy in these populations.

The review further explores emerging treatments that aim to overcome conventional limitations by adopting precision medicine approaches to target disease-specific molecular and circuit dysfunction, thereby improving patients’ quality of life (QoL) and possibly influencing cognitive decline.

Background

Decades of clinical reports and public health datasets indicate that neurodegenerative conditions like Alzheimer's disease (AD) and Parkinson's disease (PD) often co-occur with depressive syndromes and other neuropsychiatric symptoms. Recent reports estimate that more than 1 in every 3 AD or PD patients also live with depression (42% and 35%, respectively), severely undermining their quality of life (QoL) and being associated with accelerated cognitive decline.

While standard antidepressants have long been used to treat these neurodegenerative cases, a growing body of research underscores a critical limitation in their clinical efficacy: standard antidepressants target broad monoaminergic systems, but may fail to engage the highly localized, disease-specific circuit disruptions unique to neurodegeneration.

Consequently, modern research is exploring alternatives across molecular pathology, inflammatory indices, and neuroimaging data. These studies aim to map the distinct mechanisms by which neurodegeneration is linked to psychological decline. However, these studies are highly specialized and often lack generalizable methodological standardization, necessitating a holistic review of their outcomes to inform future trial design.

About the Review

This narrative review aims to address these persistent knowledge limitations by synthesizing the clinical and translational literature published primarily since 2000 across several medical databases: 1. MEDLINE, 2. Embase, 3. Web of Science, and 4. ClinicalTrials.gov.

The review synthesized evidence across molecular, cognitive, and therapeutic domains and prioritized human clinical data and data from in vivo neuroimaging investigations.

Notably, the authors presented a pooled analysis of existing positron emission tomography (PET) imaging studies in AD, thereby enabling computation of standardized mean differences (SMDs) in receptor and transporter binding between patients with AD and healthy controls.

The review further analyzed structural and functional alterations across major neurotransmitter systems, specifically serotonin, acetylcholine, glutamate, and dopamine, within specialized brain structures like the prefrontal cortex, amygdala, and striatum.

Finally, the review cross-referenced the ClinicalTrials.gov landscape of Phase II through Phase IV clinical trials to critically evaluate the historical exclusion of cognitively impaired populations from psychiatric innovation and identify next-generation therapeutic candidates that may improve patient outcomes.

Review Findings

This review synthesizes evidence suggesting that neurodegenerative depression may reflect localized, disease-specific circuit and molecular disruptions. However, the mechanistic underpinnings of depression in AD and PD patients appear distinct.

While AD features early glutamatergic excitotoxic stress and cortical network decay, PD depression is associated with altered frontostriatal and reward-processing circuits, contributing to anhedonia and other motivational symptoms. These neurobiological differences from idiopathic or late-life depression help explain the limited efficacy of conventional pharmacological antidepressant interventions in patients with AD or PD.

Encouragingly, emergent mechanism-guided therapies which are specifically designed to target AD- and PD-associated depression features may offer therapeutic promise, although direct evidence in these populations remains limited.

For example, a previous meta-analysis of intravenous ketamine trials found that the non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist achieved rapid, large symptom reductions at 24 hours (SMD = -0.77, 95% Confidence Interval [CI] -1.08 to -0.46), but ketamine has not yet been directly tested for depression in AD or PD. Similarly, the oral compound dextromethorphan-bupropion generated a significant drop in Montgomery-Åsberg Depression Rating Scale (MADRS) scores during the Phase III GEMINI trial (39.5% remission rate versus 17.3% for the placebo group), although this evidence comes from major depressive disorder rather than AD or PD depression.

For serotonergic pathways, the 5-HT4 receptor partial agonist prucalopride was associated with reduced long-term depression risks (Hazard Ratio = 0.79), but it remains exploratory and has not been evaluated as a depression treatment in AD or PD. In PD, the selective D2/D3 dopamine agonist pramipexole is now known to significantly improve depression scores over 12 weeks (mean Beck Depression Inventory difference of 1.9). Conversely, peripheral anti-inflammatory options like minocycline showed early promise in small studies but failed to show consistent benefit in larger placebo-controlled trials.

Conclusions

The present review establishes that neurodegenerative depression should not be treated solely as a comorbidity or an independently addressable condition. Instead, it requires a definitive shift from broad symptom-based prescribing toward targeted, biology-driven interventions.

While traditional monoaminergic drugs show limited benefit in AD and PD depression, precision options like extended-release ketamine formulations, KCNQ potassium channel openers, and subcortical neuromodulation, e.g., low-intensity transcranial focused ultrasound (TUS), represent promising but still largely unvalidated approaches for improving patients’ QoL and possibly modifying trajectories linked to cognitive decline.

The authors emphasize that to address the persistent limitation of translating exemplary preclinical findings into therapeutic practice, future clinical trials must incorporate biological stratification, using blood-based biomarkers, advanced neuroimaging, and multidimensional symptom tracking to match specific treatments directly to an individual's evolving neural pathology.